Skip to content

Curesis Plasma Separator

by Organon Teknika Corp.

PMA P830010

Active United States

PMA

Valid until

No expiry

PMA approval is not time-limited

FDA recalls

None found

in data synced 22 Oct 2026

Documents

PMA P830010↗

FDA record

Trust

Unverified

Registry data, not yet checked by deviCERTS. Source FDA PMA, synced 22 Oct 2026. What this means

Regulatory status

as of registry sync 22 Oct 2026

RegionAuthorizationNumberDateStatus
United StatesFDA PMAAPPR Approved 1 supplement NumberP830010 Date6 Dec 1985ApprovedStatusActive

Recalls

0 recalls · FDA

No FDA recalls found in the data synced 22 Oct 2026.

Coverage

1 jurisdiction

United States of America
  • Active
  • Expiring
  • Withdrawn
  • Listed
  • Not covered

United States — FDA PMA Active

Specification

PMA

Generic Name
Separator for therapeutic purposes, membrane automated blood cell/plasma
PMA Number
FDA Product Code
MDP
Device Class
Class III
Advisory Committee
Gastroenterology, Urology
FDA Decision
APPR Approved
PMA Supplement
S003

Overview

AI-generated summary, 18 Sep 2026

Written by a language model from registry data. Not verified by deviCERTS or the manufacturer. The registry data above is the record.

The Curesis Plasma Separator is an automated, therapeutic device designed for the separation of blood into its cellular and plasma components. Classified as a separator for blood cells and plasma, it operates to isolate plasma for therapeutic use while retaining red blood cells, platelets, and other cellular elements.

This device is intended for use in clinical settings, such as hospitals and blood banks, where plasma separation is required for therapeutic applications. Supplied as a reusable medical instrument, it requires proper sterilization and maintenance to ensure safety and functionality. The device is authorized under an FDA Premarket Approval (PMA) and falls under device class U, adhering to regulatory standards for therapeutic blood separation systems.

Other devices from Organon Teknika Corp.

See all devices from Organon Teknika Corp. →

Questions

AI-generated answers, 18 Sep 2026

Written by a language model from registry data. Not verified by deviCERTS or the manufacturer. The registry data above is the record.

  • Is the Curesis Plasma Separator designed for single-use or can it be reused in a clinical setting?

    The Curesis Plasma Separator is supplied as a reusable medical instrument. Since it is intended for therapeutic blood separation, it requires proper sterilization and maintenance between uses to ensure safety and functionality, as outlined in its FDA-authorized design.

  • What types of clinical settings is the Curesis Plasma Separator intended for?

    The device is specifically designed for use in clinical settings such as hospitals and blood banks, where plasma separation for therapeutic applications is required. Its automated design supports controlled, high-volume processing of blood components.

  • How is the Curesis Plasma Separator regulated by the FDA?

    The Curesis Plasma Separator holds an FDA Premarket Approval (PMA) under the designation P830010, confirming its compliance with regulatory standards for therapeutic blood separation systems. It falls under device class U, reflecting its role in isolating plasma while retaining cellular elements.

  • What does the device separate, and what remains in the blood after processing?

    The Curesis Plasma Separator automates the separation of blood into plasma (for therapeutic use) and cellular components, including red blood cells and platelets. The device is engineered to retain these cells while isolating plasma efficiently for further medical applications.

  • Are there multiple models or configurations of the Curesis Plasma Separator available?

    The device data lists multiple FEI numbers (e.g., 1450662, 1219343, etc.), which may correspond to different models or variants of the Curesis Plasma Separator. These identifiers suggest variations in design or functionality, though specific differences (e.g., capacity, features) would require direct consultation with the manufacturer.